Individuals’ metabolomic marker profiles may predict the onset of inflammatory bowel disease a decade in advance, underlining ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

Crohn's disease, a debilitating inflammatory bowel disease, has many known contributing factors, including bacterial changes in the microbiome that foster an inflammatory environment.

Cases of early onset colorectal cancer, occurring in people between the ages of 20 and 45, have increased in recent decades.

Warning signs of colorectal cancer include a change in bowel habits, abdominal pain and unexplained weight loss.